Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Ginkgo Bioworks Holdings, Inc. Class A Common Stock (NY:DNA)

13.38 -1.74 (-11.51%)
Streaming Delayed Price Updated: 3:32 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Ginkgo Bioworks Holdings, Inc. Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Dell, Select Medical, Century Aluminum And Other Big Stocks Moving Higher On Wednesday
 
Via Benzinga
AI Unlocks Secrets of Intrinsically Disordered Proteins: A Paradigm Shift in Biomedical Design
A groundbreaking advancement in artificial intelligence has opened new frontiers in understanding and designing intrinsically disordered proteins (IDPs), a class of biomolecules previously considered... 
Via TokenRing AI
Topics Artificial Intelligence Derivatives
5 Healthcare Stocks On Fire This Week
Healthcare stocks SNOA, EVOK, KALA, DNA, & SNGX soar with massive momentum gains, signaling breakout potential in biotech & pharma. 
Via Benzinga
Earnings Scheduled For August 7, 2025
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Earnings Scheduled For February 25, 2025
 
Via Benzinga
Earnings Scheduled For November 12, 2024
 
Via Benzinga
Insights into Ginkgo Bioworks Holdings's Upcoming Earnings
 
Via Benzinga
Ginkgo Bioworks Holdings Inc (NYSE:DNA) Fits the Minervini Trend Template with Strong Technicals and High-Growth Momentum
Ginkgo Bioworks (DNA) meets Minervini Trend Template criteria with strong technicals, earnings growth, and momentum, making it a high-growth stock to watch. 
Via Chartmill
Hewlett Packard Enterprise, Magnite, GMS And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
Nvidia-Backed Recursion, Ginkgo Bioworks Rally Following FDA's Decision To End Animal Testing
FDA announces plan to end mandatory animal testing of new drugs, replacing it with more effective and human relevant methods. 
Via Benzinga
Topics Animal Testing
Fastenal Posts Better-Than-Expected Sales, Joins Simulations Plus, Certara And Other Big Stocks Moving Higher On Friday
 
Via Benzinga
From Promise to Peril: The Downfall of Ginkgo Bioworks
 
Via Benzinga
Flywire Posts Downbeat Results, Joins Lemonade, Ginkgo Bioworks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
 
Via Benzinga
US Stocks Likely To Open Higher Ahead Of Nvidia Earnings: S&P 500's Four-Day Fall Was A 'Non-Event,' Says Expert
U.S. stock futures rose on Wednesday following two consecutive days of mixed close this week. All futures advanced in premarket trading. 
Via Benzinga
Topics Stocks
Why ZoomInfo Technologies Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
Why Coherent Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
 
Via Benzinga
What's Going On With Ginkgo Bioworks Stock This Week?
Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares continue to trade higher after rising nearly 10% on Tuesday. Here's a look at what's going on. 
Via Benzinga
Why Ginkgo Bioworks Holdings Stock Raced 9% Higher Today
The company is forging ahead with next-generation drug development solutions. 
Via The Motley Fool
Google Cloud Expands Its Partnership With Ginkgo Bioworks For Two New AI-Tools Faster Drug Development
Ginkgo Bioworks introduces a protein large language model and API, developed with Google Cloud, to streamline drug discovery by leveraging AI and proprietary biological data, offering affordable and... 
Via Benzinga
Topics Artificial Intelligence
Ginkgo Bioworks Stock Is Rallying Tuesday: Here's Why
Ginkgo Bioworks Holdings Inc (NYSE:DNA) shares are surging Tuesday after the company announced the launch of its new protein large language model (LLM) built on Google Cloud. 
Via Benzinga
Compass Minerals, Torrid Holdings, Icahn Enterprises, Hewlett Packard Enterprise And Other Big Stocks Moving Higher On Tuesday
 
Via Benzinga
Down a Monstrous 90% This Year, Is There Any Hope Left for Ginkgo Bioworks Investors?
Could this beaten-down stock turn things around in the near future? 
Via The Motley Fool
2 Big Risks and 2 Big Opportunities for Ginkgo Bioworks Stock
The risks may resolve in a year or so but seizing the opportunities will take longer. 
Via The Motley Fool
This 1 AI Stock Could Revolutionize Biotech and Pharma
The company is using artificial intelligence, and planning to help others use AI empowered by its data collection. 
Via The Motley Fool
Topics Artificial Intelligence
Down 88% in 1 Year, What's Next for Ginkgo Bioworks Stock?
Its ambitious business model may not be sustainable. 
Via The Motley Fool
Down 86% This Year, Is Ginkgo Bioworks Stock a Bargain Now?
Have shares of the troubled life sciences business fallen too far? 
Via The Motley Fool
Prediction: Artificial Intelligence Will Lead to Higher Returns With Biotech Stocks
Efficiency in core processes is set to increase substantially due to AI. 
Via The Motley Fool
Topics Artificial Intelligence
DNA Stock Earnings: Ginkgo Bioworks Holdings Misses EPS, Beats Revenue for Q2 2024
DNA stock results show that Ginkgo Bioworks Holdings missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
DNA Stock Alert: Ginkgo Bioworks Plunges on Plan for Reverse Stock Split
Ginkgo Bioworks stock is falling hard on Friday as DNA investors prepare to vote on a reverse stock split later this month. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 9
...
13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.